The antinociceptive effect of the asthma drug ibudilast in rat models of peripheral and central neuropathic pain

Aldric T. Hama, Alex Broadhead, Daniel S. Lorrain, Jacqueline Sagen

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Ibudilast, an asthma drug, has demonstrated antinociceptive effects in several rat models of peripheral neuropathic pain, and a proposed mechanism of action is the inhibition of release of the cytokine tumor necrosis factor-α (TNF-α) from activated spinal microglia. Spinal glial activation has also been demonstrated in rat models of central neuropathic pain following spinal cord injury (SCI). The current study evaluated the effect of a short course of treatment with ibudilast on SCI-induced pain, and for comparison, following a chronic constriction injury (CCI; the Bennett model) of the sciatic nerve in rats. The effects of ibudilast treatment on spinal (SCI and CCI rats), and nerve tissue (CCI only) TNF-α content were also evaluated. Following an acute midthoracic SCI with a microvascular clip (20-g force), hindpaw withdrawal thresholds were significantly decreased, indicating below-level cutaneous tactile hypersensitivity. Likewise, unilateral loose ligation of the sciatic nerve led to a robust ipsilateral tactile hypersensitivity. Rats were treated with either ibudilast (10 mg/kg IP) or vehicle (2 mL/kg) during the period of robust and steady hindpaw hypersensitivity for each model-CCI rats were treated 14-16 days post-surgery, and SCI rats were treated 30-32 days post-surgery-and tested daily. Ibudilast ameliorated hindpaw hypersensitivity in both SCI and CCI rats, whereas vehicle treatment had no effect. Interestingly, repeated treatment led to increased baseline thresholds, beyond the duration of the drug half-life, suggesting persistent changes in neuropathic pain processing. In SCI rats, an increase in TNF-α content in spinal tissue rostral to the SCI was observed. Ibudilast treatment did not significantly alter this increase. In rats with a CCI, TNF-α content was markedly increased in the ipsilateral sciatic nerve and was partially reduced following ibudilast, but not vehicle, treatment. Ibudilast could be useful for the treatment of neuropathic pain of central as well as peripheral origin.

Original languageEnglish
Pages (from-to)600-610
Number of pages11
JournalJournal of Neurotrauma
Volume29
Issue number3
DOIs
StatePublished - Feb 10 2012

Fingerprint

Neuralgia
Spinal Cord Injuries
Asthma
Pharmaceutical Preparations
Hypersensitivity
Sciatic Nerve
Tumor Necrosis Factor-alpha
Touch
Ambulatory Surgical Procedures
Therapeutics
ibudilast
Nerve Tissue
Microglia
Surgical Instruments
Constriction
Neuroglia
Ligation
Half-Life
Cytokines
Pain

Keywords

  • allodynia
  • AV-411
  • glia
  • off-label use
  • peripheral neuropathy
  • spinal cord injury
  • tumor necrosis factor-α

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

The antinociceptive effect of the asthma drug ibudilast in rat models of peripheral and central neuropathic pain. / Hama, Aldric T.; Broadhead, Alex; Lorrain, Daniel S.; Sagen, Jacqueline.

In: Journal of Neurotrauma, Vol. 29, No. 3, 10.02.2012, p. 600-610.

Research output: Contribution to journalArticle

@article{969b88b64d044333bbb769c90265aed0,
title = "The antinociceptive effect of the asthma drug ibudilast in rat models of peripheral and central neuropathic pain",
abstract = "Ibudilast, an asthma drug, has demonstrated antinociceptive effects in several rat models of peripheral neuropathic pain, and a proposed mechanism of action is the inhibition of release of the cytokine tumor necrosis factor-α (TNF-α) from activated spinal microglia. Spinal glial activation has also been demonstrated in rat models of central neuropathic pain following spinal cord injury (SCI). The current study evaluated the effect of a short course of treatment with ibudilast on SCI-induced pain, and for comparison, following a chronic constriction injury (CCI; the Bennett model) of the sciatic nerve in rats. The effects of ibudilast treatment on spinal (SCI and CCI rats), and nerve tissue (CCI only) TNF-α content were also evaluated. Following an acute midthoracic SCI with a microvascular clip (20-g force), hindpaw withdrawal thresholds were significantly decreased, indicating below-level cutaneous tactile hypersensitivity. Likewise, unilateral loose ligation of the sciatic nerve led to a robust ipsilateral tactile hypersensitivity. Rats were treated with either ibudilast (10 mg/kg IP) or vehicle (2 mL/kg) during the period of robust and steady hindpaw hypersensitivity for each model-CCI rats were treated 14-16 days post-surgery, and SCI rats were treated 30-32 days post-surgery-and tested daily. Ibudilast ameliorated hindpaw hypersensitivity in both SCI and CCI rats, whereas vehicle treatment had no effect. Interestingly, repeated treatment led to increased baseline thresholds, beyond the duration of the drug half-life, suggesting persistent changes in neuropathic pain processing. In SCI rats, an increase in TNF-α content in spinal tissue rostral to the SCI was observed. Ibudilast treatment did not significantly alter this increase. In rats with a CCI, TNF-α content was markedly increased in the ipsilateral sciatic nerve and was partially reduced following ibudilast, but not vehicle, treatment. Ibudilast could be useful for the treatment of neuropathic pain of central as well as peripheral origin.",
keywords = "allodynia, AV-411, glia, off-label use, peripheral neuropathy, spinal cord injury, tumor necrosis factor-α",
author = "Hama, {Aldric T.} and Alex Broadhead and Lorrain, {Daniel S.} and Jacqueline Sagen",
year = "2012",
month = "2",
day = "10",
doi = "10.1089/neu.2011.1863",
language = "English",
volume = "29",
pages = "600--610",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - The antinociceptive effect of the asthma drug ibudilast in rat models of peripheral and central neuropathic pain

AU - Hama, Aldric T.

AU - Broadhead, Alex

AU - Lorrain, Daniel S.

AU - Sagen, Jacqueline

PY - 2012/2/10

Y1 - 2012/2/10

N2 - Ibudilast, an asthma drug, has demonstrated antinociceptive effects in several rat models of peripheral neuropathic pain, and a proposed mechanism of action is the inhibition of release of the cytokine tumor necrosis factor-α (TNF-α) from activated spinal microglia. Spinal glial activation has also been demonstrated in rat models of central neuropathic pain following spinal cord injury (SCI). The current study evaluated the effect of a short course of treatment with ibudilast on SCI-induced pain, and for comparison, following a chronic constriction injury (CCI; the Bennett model) of the sciatic nerve in rats. The effects of ibudilast treatment on spinal (SCI and CCI rats), and nerve tissue (CCI only) TNF-α content were also evaluated. Following an acute midthoracic SCI with a microvascular clip (20-g force), hindpaw withdrawal thresholds were significantly decreased, indicating below-level cutaneous tactile hypersensitivity. Likewise, unilateral loose ligation of the sciatic nerve led to a robust ipsilateral tactile hypersensitivity. Rats were treated with either ibudilast (10 mg/kg IP) or vehicle (2 mL/kg) during the period of robust and steady hindpaw hypersensitivity for each model-CCI rats were treated 14-16 days post-surgery, and SCI rats were treated 30-32 days post-surgery-and tested daily. Ibudilast ameliorated hindpaw hypersensitivity in both SCI and CCI rats, whereas vehicle treatment had no effect. Interestingly, repeated treatment led to increased baseline thresholds, beyond the duration of the drug half-life, suggesting persistent changes in neuropathic pain processing. In SCI rats, an increase in TNF-α content in spinal tissue rostral to the SCI was observed. Ibudilast treatment did not significantly alter this increase. In rats with a CCI, TNF-α content was markedly increased in the ipsilateral sciatic nerve and was partially reduced following ibudilast, but not vehicle, treatment. Ibudilast could be useful for the treatment of neuropathic pain of central as well as peripheral origin.

AB - Ibudilast, an asthma drug, has demonstrated antinociceptive effects in several rat models of peripheral neuropathic pain, and a proposed mechanism of action is the inhibition of release of the cytokine tumor necrosis factor-α (TNF-α) from activated spinal microglia. Spinal glial activation has also been demonstrated in rat models of central neuropathic pain following spinal cord injury (SCI). The current study evaluated the effect of a short course of treatment with ibudilast on SCI-induced pain, and for comparison, following a chronic constriction injury (CCI; the Bennett model) of the sciatic nerve in rats. The effects of ibudilast treatment on spinal (SCI and CCI rats), and nerve tissue (CCI only) TNF-α content were also evaluated. Following an acute midthoracic SCI with a microvascular clip (20-g force), hindpaw withdrawal thresholds were significantly decreased, indicating below-level cutaneous tactile hypersensitivity. Likewise, unilateral loose ligation of the sciatic nerve led to a robust ipsilateral tactile hypersensitivity. Rats were treated with either ibudilast (10 mg/kg IP) or vehicle (2 mL/kg) during the period of robust and steady hindpaw hypersensitivity for each model-CCI rats were treated 14-16 days post-surgery, and SCI rats were treated 30-32 days post-surgery-and tested daily. Ibudilast ameliorated hindpaw hypersensitivity in both SCI and CCI rats, whereas vehicle treatment had no effect. Interestingly, repeated treatment led to increased baseline thresholds, beyond the duration of the drug half-life, suggesting persistent changes in neuropathic pain processing. In SCI rats, an increase in TNF-α content in spinal tissue rostral to the SCI was observed. Ibudilast treatment did not significantly alter this increase. In rats with a CCI, TNF-α content was markedly increased in the ipsilateral sciatic nerve and was partially reduced following ibudilast, but not vehicle, treatment. Ibudilast could be useful for the treatment of neuropathic pain of central as well as peripheral origin.

KW - allodynia

KW - AV-411

KW - glia

KW - off-label use

KW - peripheral neuropathy

KW - spinal cord injury

KW - tumor necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=84857306382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857306382&partnerID=8YFLogxK

U2 - 10.1089/neu.2011.1863

DO - 10.1089/neu.2011.1863

M3 - Article

C2 - 21806469

AN - SCOPUS:84857306382

VL - 29

SP - 600

EP - 610

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 3

ER -